Literature DB >> 20373144

The reality of dietary compliance in the management of phenylketonuria.

Anita MacDonald1, Hulya Gokmen-Ozel, Margreet van Rijn, Peter Burgard.   

Abstract

In phenylketonuria (PKU), it is common for blood phenylalanine (Phe) concentrations to be outside optimal target ranges, particularly in teenagers and adults, indicating inadequate compliance. It is well known that significant noncompliance exists, and the situation in PKU would appear no different than other chronic conditions. In PKU, compliance is complex, being subject to diverse definitions, and factors influencing compliance include the nature and nurture of the patient, as well as the inconvenience, cost and availability of dietary treatment. It is also a dynamic process, with many patients changing between a state of compliance and partial and noncompliance. In PKU, compliance has received little rigorous study, and there have been few observational reports identifying barriers and behaviors impacting dietary compliance. Compliance assessment measures remain inadequately defined. The direct assessment of blood Phe concentration is perhaps the best overall measure, but there is no universal agreement about the number of Phe concentrations that should be within target range and frequency or timing of measurement. Although no one strategy for improving compliance is universally effective, and an individualized approach to noncompliance is essential, it is important to have clear evidence about the most effective strategies in achieving long-term dietary adherence in PKU.

Entities:  

Mesh:

Year:  2010        PMID: 20373144     DOI: 10.1007/s10545-010-9073-y

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  33 in total

1.  Influence of knowledge of the disease on metabolic control in phenylketonuria.

Authors:  Jolita Bekhof; Francjan J van Spronsen; Matty R Crone; Margreet van Rijn; Carin G M Oudshoorn; Paul H Verkerk
Journal:  Eur J Pediatr       Date:  2003-04-08       Impact factor: 3.183

2.  Behavioural factors related to metabolic control in patients with phenylketonuria.

Authors:  M R Crone; F J van Spronsen; K Oudshoorn; J Bekhof; G van Rijn; P H Verkerk
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

Review 3.  "Why do they do that?" The compliance conundrum.

Authors:  Thomas E Nevins
Journal:  Pediatr Nephrol       Date:  2005-05-24       Impact factor: 3.714

4.  Does a single plasma phenylalanine predict quality of control in phenylketonuria?

Authors:  A MacDonald; G W Rylance; D Asplin; S K Hall; I W Booth
Journal:  Arch Dis Child       Date:  1998-02       Impact factor: 3.791

5.  Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet.

Authors:  A MacDonald; G Rylance; S K Hall; D Asplin; I W Booth
Journal:  Arch Dis Child       Date:  1996-05       Impact factor: 3.791

Review 6.  What do we mean by adherence to treatment and advice for living with diabetes? A review of the literature on definitions and measurements.

Authors:  H Hearnshaw; A Lindenmeyer
Journal:  Diabet Med       Date:  2006-07       Impact factor: 4.359

7.  Does maternal knowledge impact blood phenylalanine concentration in Turkish children with phenylketonuria?

Authors:  H Gokmen Ozel; T Kucukkasap; G Koksal; H S Kalkanoglu Sivri; A Dursun; A Tokatli; T Coskun
Journal:  J Inherit Metab Dis       Date:  2008-06-27       Impact factor: 4.982

8.  A new amino acid mixture permits new approaches to the treatment of phenylketonuria.

Authors:  N R Buist; A P Prince; K L Huntington; J M Tuerck; D D Waggoner
Journal:  Acta Paediatr Suppl       Date:  1994-12

9.  Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing.

Authors:  F J van Spronsen; M van Rijn; T van Dijk; G P Smit; D J Reijngoud; R Berger; H S Heymans
Journal:  Pediatrics       Date:  1993-10       Impact factor: 7.124

10.  Knowledge, compliance and serum phenylalanine concentrations in adolescents and adults with phenylketonuria and the effect of a patient-focused educational resource.

Authors:  S J Durham-Shearer; P A Judd; K Whelan; J E Thomas
Journal:  J Hum Nutr Diet       Date:  2008-10       Impact factor: 3.089

View more
  70 in total

1.  Nutritional status in patients with phenylketonuria using glycomacropeptide as their major protein source.

Authors:  A Pinto; M F Almeida; P C Ramos; S Rocha; A Guimas; R Ribeiro; E Martins; A Bandeira; A MacDonald; J C Rocha
Journal:  Eur J Clin Nutr       Date:  2017-04-12       Impact factor: 4.016

2.  Nutritional Changes and Micronutrient Supply in Patients with Phenylketonuria Under Therapy with Tetrahydrobiopterin (BH(4)).

Authors:  A G Thiele; J F Weigel; B Ziesch; C Rohde; U Mütze; U Ceglarek; J Thiery; A S Müller; W Kiess; S Beblo
Journal:  JIMD Rep       Date:  2012-10-17

3.  Successful Live Birth following Preimplantation Genetic Diagnosis for Phenylketonuria in Day 3 Embryos by Specific Mutation Analysis and Elective Single Embryo Transfer.

Authors:  Stuart Lavery; Dima Abdo; Mara Kotrotsou; Geoff Trew; Michalis Konstantinidis; Dagan Wells
Journal:  JIMD Rep       Date:  2012-03-31

4.  The role of integrated behavioral health in caring for patients with metabolic disorders.

Authors:  Neelkamal Soares; Roger W Apple; Shibani Kanungo
Journal:  Ann Transl Med       Date:  2018-12

5.  Practical aspects of recruitment and retention in clinical trials of rare genetic diseases: the phenylketonuria (PKU) experience.

Authors:  Stephanie J DeWard; Ashley Wilson; Heather Bausell; Ashley S Volz; Kimberly Mooney
Journal:  J Genet Couns       Date:  2013-09-08       Impact factor: 2.537

6.  Demographic and Psychosocial Influences on Treatment Adherence for Children and Adolescents with PKU: A Systematic Review.

Authors:  Emma Medford; Dougal Julian Hare; Anja Wittkowski
Journal:  JIMD Rep       Date:  2017-08-25

7.  Tetrahydrobiopterin (BH4) in PKU: effect on dietary treatment, metabolic control, and quality of life.

Authors:  B Ziesch; J Weigel; A Thiele; U Mütze; C Rohde; U Ceglarek; J Thiery; W Kiess; S Beblo
Journal:  J Inherit Metab Dis       Date:  2012-03-06       Impact factor: 4.982

8.  Creatine plus pyruvate supplementation prevents oxidative stress and phosphotransfer network disturbances in the brain of rats subjected to chemically-induced phenylketonuria.

Authors:  Vanessa Trindade Bortoluzzi; Letícia Brust; Thales Preissler; Itiane Diehl de Franceschi; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2019-07-27       Impact factor: 3.584

9.  Unrestricted fruits and vegetables in the PKU diet: a 1-year follow-up.

Authors:  C Rohde; U Mütze; S Schulz; A G Thiele; U Ceglarek; J Thiery; A S Mueller; W Kiess; S Beblo
Journal:  Eur J Clin Nutr       Date:  2014-01-08       Impact factor: 4.016

Review 10.  Up to date knowledge on different treatment strategies for phenylketonuria.

Authors:  Amaya Bélanger-Quintana; Alberto Burlina; Cary O Harding; Ania C Muntau
Journal:  Mol Genet Metab       Date:  2011-08-16       Impact factor: 4.797

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.